Novel homozygous OSGEP gene pathogenic variants in two unrelated patients with Galloway-Mowat syndrome : case report and review of the literature by Domingo-Gallego, Andrea et al.
CASE REPORT Open Access
Novel homozygous OSGEP gene
pathogenic variants in two unrelated
patients with Galloway-Mowat syndrome:
case report and review of the literature
Andrea Domingo-Gallego1,2, Mónica Furlano2, Marc Pybus1,2, Daniel Barraca3, Ana Belén Martínez3,
Emiliano Mora Muñoz4, Roser Torra2† and Elisabet Ars1,2*†
Abstract
Background: Galloway-Mowat syndrome (GAMOS) is a rare autosomal recessive disorder characterized by early-
onset nephrotic syndrome and microcephaly with brain anomalies. WDR73 pathogenic variants were described as
the first genetic cause of GAMOS and, very recently, four novel causative genes, OSGEP, LAGE3, TP53RK, and TPRKB,
have been identified.
Case presentation: We present the clinical and genetic characteristics of two unrelated infants with clinical
suspicion of GAMOS who were born from consanguineous parents. Both patients showed a similar clinical
presentation, with early-onset nephrotic syndrome, microcephaly, brain atrophy, developmental delay, axial
hypotonia, and early fatality. We identified two novel likely disease-causing variants in the OSGEP gene. These two
cases, in conjunction with the findings of a literature review, indicate that OSGEP pathogenic variants are associated
with an earlier onset of nephrotic syndrome and shorter life expectancy than WDR73 pathogenic variants.
Conclusions: Our findings expand the spectrum of pathogenic variants in the OSGEP gene and, taken in
conjunction with the results of the literature review, suggest that the OSGEP gene should be considered the main
known monogenic cause of GAMOS. Early genetic diagnosis of GAMOS is of paramount importance for genetic
counseling and family planning.
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Background
Galloway-Mowat syndrome (GAMOS) (OMIM #251300)
is a rare autosomal recessive syndrome first described in
1968. It is a clinically heterogeneous condition character-
ized by early-onset nephrotic syndrome associated with
microcephaly, gyral abnormalities of the brain, and
delayed psychomotor development. Most patients also
present dysmorphic facial features, including hypertelor-
ism, ear abnormalities, and micrognathia. Most affected
individuals die in early childhood [1, 2]. The estimated
prevalence is < 1/1,000,000 but it is likely that many cases
remain misdiagnosed or undiagnosed.
Truncating variants in WDR73 gene were described as
the first monogenic cause of GAMOS in two families
[3]. The protein encoded by this gene is implicated in
the regulation of the microtubule network during cell
cycle progression, proliferation, and survival [3–5].
Homozygous missense variants in the WDR73 gene were
later reported [6, 7]. Recently, pathogenic variants in the
OSGEP, LAGE3, TP53RK, and TPRKB genes have been
identified as novel monogenic causes of GAMOS. These
genes encode four subunits of the evolutionary highly
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conserved KEOPS (kinase, endopeptidase, and other
proteins of small size) complex. This complex plays
an important role in brain and renal development. To
date, the genetic cause of GAMOS has been reported
in 54 families: OSGEP in 26 (48.15%), WDR73 in 19
(35.18%), TP53RK in 4 (7.40%), LAGE3 in 3 (5.55%),
and TPRKB in 2 (3.70%) [2–11].
Here, we report two unrelated patients with GAMOS
carrying homozygous pathogenic variants in the newly
identified OSGEP gene.
Case presentation
Patient 1 was a first-child male born to healthy consan-
guineous parents from Spain with no previous family
history of kidney disease (Table 1, Fig. 1A). He was born
at 39.4 weeks of gestation. Birth weight was 3400 g,
height was 51 cm, and head circumference was 34 cm,
with no dysmorphic features. Forty-five days after birth,
the patient was diagnosed as having congenital nephrotic
syndrome with severe proteinuria, hypertension, and
hypothyroidism. He also presented edema, hyperkalemia,
hyponatremia, and hypomagnesemia. Renal ultrasound
showed poor corticomedullary differentiation in the right
kidney. Renal biopsy showed diffuse mesangial sclerosis,
tubular atrophy, and primitive glomeruli (Fig. 1C). The pa-
tient progressed to end-stage renal disease and required
peritoneal dialysis. He also presented left eye evisceration,
dry right eye, and gastroesophageal reflux. At 5 months of
age, the neurological examination revealed microcephaly
with a head circumference of 38.5 cm (percentile < 1, −
4.72 SD), severe psychomotor delay for his age, and axial
hypotonia. Cranial magnetic resonance imaging (CMRI)
revealed brain atrophy and absence of normal myelination
of the brainstem, cerebellar white matter, bilateral hemi-
spheric white matter, internal capsules, and corpus callo-
sum as well as abnormal intensity signal in the dentate
nucleus and thalamus (Fig. 1D). In view of the congenital
nephrotic syndrome and microcephaly with brain anomal-
ies, a clinical diagnosis of GAMOS was suspected. The pa-
tient presented progressive neurological deterioration and
died at 8months of age.
Patient 2 was a female infant with normal karyotype
(46, XX) born to healthy consanguineous parents from
Pakistan. The patient had two healthy sisters and there
was no family history of kidney disease (Table 1, Fig. 2a).
She was born at 40.3 weeks of gestation. Birth weight
was 2940 g, height was 49 cm, and head circumference
was 32 cm with signs of microcephaly. Screening for
Table 1 Clinical data of patients 1 and 2
Clinical features Patient 1 Patient 2
Sex Male Female
Age at death 8 months 7 months
Origin Spanish Pakistani
Neonatal profile (at birth)
Gestational period (weeks) 39.4 40.3
Weight (g) 3400 (58th percentile) 2940 (17th percentile)
Height (cm) 51 (70th percentile) 49 (30th percentile)
Head circumference (cm) 34 (28th percentile) 32 (3rd percentile)
Renal phenotype
Onset of NS (days) 45 75
Renal biopsy DMS, tubular atrophy, primitive glomeruli Increased glomerular mesangial matrix
Renal ultrasound Poor corticomedullary differentiation Cortical hyperechogenicity
Hyperkalemia Yes No
Hypomagnesemia Yes No
Neurological involvement
Brain MRI Microcephaly, brain atrophy, poor myelination Microcephaly, brain atrophy
Developmental delay Yes Yes
Axial hypotonia Yes Yes
Skeletal abnormalities No Arachnodactyly
Dysmorphic features No Yes (wide nasal bridge, retrognathia,
low set ears)
Others Dry right eye
Gastroesophageal reflux
Epileptiform activity
Seizures
DMS Diffuse mesangial sclerosis, NS nephrotic syndrome
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metabolic disorders and cerebral ultrasound were normal.
The patient presented dysmorphic features (wide nasal
bridge, aquiline nose and retrognathia, low set ears, and
arachnodactyly) with axial hypotonia and poor eye contact.
Seventy-five days after birth, she presented with nephrotic
range proteinuria, hypoproteinemia with severe hypoal-
buminemia, hypertriglyceridemia and hypercholesterol-
emia. Serum creatinine and urea were normal. Abdominal
a
d
b
c
Fig. 1 a Pedigree of patient 1 with a likely pathogenic OSGEP variant, c.81C > G p.(Asn27Lys), in homozygosity while his consanguineous parents
are healthy heterozygous carriers. b The identified missense variant c.81C > G p.(Asn27Lys) affects a totally conserved amino acid N27 in OSGEP
orthologs. c Silver-stained renal biopsy from patient 1 showed glomerular collapse with mesangial matrix increase, atrophic tubules, and
interstitial fibrosis on light microscopy. d CMRI performed in patient 1 at 8 months of age: sagittal 3 Dimensional Imaging T1 sequence (a), axial
reconstructions (b–e), and axial Turbo Spin Echo (TSE) T2 (f–j). k–o: Sequence TSE T2 of normal control individual. MRI revealed craniofacial
disproportion in relation to microcephaly (a); supratentorial cortico-subcortical atrophy with increased extra-axial space, prominence of the frontal
horns, and thinning of the corpus callosum (red arrow in a); bilateral subdural frontoparietal hygromas (red asterisks in h–j); and atrophy of the
basal ganglia (h). A decrease in the number and depth of the grooves was observed (h–j) and there was an absence of normal myelination of
the brainstem (red arrow in f), cerebellar peduncles (blue arrow in f), internal capsules (red arrow in h), and white bihemispheric substance
(arrows in i and j). Hypointense T2 signal of the thalamus was evident (blue arrow in h). Enucleation of the left eye is denoted by the yellow
arrow in f. Finally, there was an increase in the thickness of the cranial and facial subcutaneous cellular tissue (green arrows in a and b)
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ultrasound showed normal-sized kidneys and correct cor-
ticomedullary differentiation with cortical hyperechogeni-
city, bilateral pleural effusion, and a discrete amount of
fluid in the abdominal cavity. Renal biopsy showed one
glomerulus with increased mesangial matrix and two nor-
mal glomeruli; fibrosis and tubular atrophy were absent.
CMRI revealed severe brain atrophy with normal cerebel-
lum and brainstem. Electroencephalogram showed normal
brain activity with low-amplitude brain waves and occa-
sional frontal left epileptiform activity. The patient evolved
with failure to thrive, anemia, and electrolyte disorders
and finally died from cardiorespiratory arrest in a sepsis
context at 7months of age.
Genetic study
Variant analyses of patients 1 and 2 were performed by
targeted massive parallel sequencing using an updated
version of our kidney disease gene panel that includes
more than 200 genes causative of or associated with
inherited kidney diseases (including WDR73, TPRKB,
TP53RK, LARGE3, and OSGEP genes) [12].
Briefly, libraries were prepared according to the manu-
facturer’s standard protocol, NimbleGen SeqCap EZ
Library SR version 4.3. Patients’ DNAs were fragmented
and hybridized to the custom NimbleGen SeqCap EZ
Choice gene panel and sequenced on a NextSeq 500
instrument (Illumina). Sequence data analysis was per-
formed using an open-source in-house bioinformatic
pipeline, as previously reported [12–14]. The mean depth
of coverage per exon of OSGEP ranged from 153 to 433,
with 100% of the bases covered at least 100X. Predic-
tion of pathogenicity was evaluated using different bio-
informatic algorithms (DANN, GERP, dbNSFP.FATHMM,
LRT, MetaLR, MetaSVM, MutationAssessor, PROVEAN,
SIFT, and MutationTaster). Clinical interpretation of vari-
ants was based on American College of Medical Genetics
(ACMG) recommendations [15]. All candidate pathogenic
variants were validated by conventional polymerase chain
reaction amplification and Sanger sequencing. Familial
segregation analysis was assessed. Analysis of copy num-
ber variations (CNVs) was performed using CoNVaDING
(copy number variation detection in next-generation
sequencing gene panels) software [16].
Patient 1 carried a homozygous missense variant
c.81C > G p.(Asn27Lys) in exon 1 of the OSGEP gene
(NM_017807), not previously described in the literature.
This variant was predicted to be pathogenic by seven
prediction tools (DANN, GERP, LRT, MutationAssessor,
MutationTaster, SIFT, and PROVEAN) and benign by
three (dbNSFP.FATHMM, MetaLR, and MetaSVM).
This variant altered an evolutionarily highly conserved
residue and was absent from the population databases
Genome Aggregation Database (gnomAD) and 1000
Genomes (Fig. 1B). Segregation analysis showed that
both parents were heterozygous carriers of this OSGEP
variant (Fig. 1A). We concluded that this variant was
likely pathogenic (Table 2).
Patient 2 carried a homozygous missense variant
c.157A > T p.(Ile53Phe) localized in exon 2 of the OSGEP
gene. This variant has not been previously reported in
a b
Fig. 2 a Pedigree of the family of patient 2 with a likely pathogenic OSGEP variant c.157A > T p.(Ile53Phe) in homozygosity in the proband
(arrow) and heterozygosity in her healthy parents. b Conservation of I53 in OSGEP orthologs to C. elegans
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literature. The variant c.157A >T p.(Ile53Phe) was pre-
dicted to be pathogenic by five prediction tools (DANN,
LRT, MutationAssessor, MutationTaster, and PROVEAN)
and benign by five (GERP, dbNSFP.FATHMM, MetaLR,
SIFT, and MetaSVM). This variant was conserved in
OSGEP orthologs to C. elegans and is extremely rare in the
general population (Fig. 2b), with a minor allele frequency
in South Asians is 0.00009799 (3 of 30,782 sequenced
alleles, no homozygous individuals) in the gnomAD data-
base. The global allele frequency was lower than the 0.0001
threshold for recessive gene OSGEP. The parents were
confirmed to be heterozygous carriers (Fig. 2a). We classi-
fied this variant as likely pathogenic (Table 2).
Discussion and conclusions
We report two patients who presented with nephrotic
syndrome with onset at < 3 months old, primary micro-
cephaly, and developmental delay, which are hallmarks
of GAMOS. Both patients carried homozygous likely
disease-causing variants in the OSGEP gene. This gene
was recently identified as causative of GAMOS in a large
cohort of 907 individuals with nephrotic syndrome [2].
Pathogenic variants in one of the four genes TP53RK,
TPRKB, LAGE3, and OSGEP, encoding KEOPS complex
subunits, were found in 37 out of 91 patients with
GAMOS. Independently, a homozygous pathogenic vari-
ant in the OSGEP gene was reported in two siblings with
a similar renal-neurological phenotype, also by whole ex-
ome sequencing [8].
The OSGEP gene encodes the O-sialoglycoprotein endo-
peptidase enzyme, which regulates the second biosynthetic
step in the formation of N-6-threonylcarbamoyladenosine
in the cytosol, essential for mRNA translational initiation
and efficiency. The highly conserved KEOPS complex is
implicated in several cell processes, such as control of telo-
mere length, telomere-associated DNA damage response
signaling, and genome maintenance. Zebrafish larvae
knockout of the osgep gene resulted in primary microceph-
aly, with increased apoptosis in the brain compared with
controls and early lethality. Knockout mouse embryos also
showed microcephaly compared with wild-type embryos.
Neither mutant fish nor mice showed any renal phenotype,
possibly due to embryonic early lethality [2].
Great strides have been made in the understanding of
GAMOS disease over the past 4 years, with the identifi-
cation of its genetic bases in some patients. However,
the genetic etiology of more than three-quarters of
patients with a clinical diagnosis of GAMOS remains
elusive, suggesting that additional causative genes re-
main to be identified. Currently, the principal known
causative genes of GAMOS are OSGEP and WDR73.
A review of the literature based on 31 patients (26
families) bearing OSGEP pathogenic variants and 23
patients (13 families) with WDR73 pathogenic variants
indicates that OSGEP causes earlier onset of nephrotic syn-
drome than WDR73 [2–4, 6–10]. Eighty percent (25/31) of
patients with OSGEP pathogenic variants developed neph-
rotic syndrome with a mean age at onset of 10.36months
(ranging onset from birth to 13 years). In comparison,
35% (8/23) of patients with WDR73 pathogenic vari-
ants presented nephrotic syndrome at a mean age of
7.7 years (ranging from 0.5 to 16 years). Our two pa-
tients carrying OSGEP pathogenic variants presented
with nephrotic syndrome before 3 months of age.
Renal manifestations described in GAMOS patients
vary from isolated proteinuria to steroid-resistant neph-
rotic syndrome, and some patients even have no renal
alterations during follow-up period [2–8]. Intrafamilial
clinical variability has also been described in GAMOS.
For instance, two siblings carrying a WDR73 pathogenic
variant manifested contrasting renal phenotype [3]. One
of the affected siblings presented with nephrotic syn-
drome at the age of 5 years, rapidly developed chronic
renal insufficiency, and died after a month, while the
other had no renal symptoms at the age of 7 years [3]. A
homozygous OSGEP pathogenic variant, c.974A > G
p.(Arg325Gln), has also been associated with renal tubu-
lar anomalies [10]. It was detected in a girl with
magnesium-wasting tubulopathy and partial Fanconi
syndrome with a normal glomerular filtration rate who
never developed nephrotic syndrome [10]. Interestingly,
this variant was previously identified in two siblings with
severe hypomagnesemia, hypercalciuria, and proteinuria
but normal albumin levels [8]. The authors raised the
question of whether these patients should be considered
to be affected by a different clinical entity [8, 10].
The review of the literature also indicates that patients
with OSGEP pathogenic variants have a shorter life ex-
pectancy than those with WDR73 pathogenic variants.
Seventy-one percent (22/31) of patients with OSGEP
pathogenic variants died at a mean age of 1.5 years (ran-
ging from 6 weeks to 8 years). In line with these reported
cases, our patients died at 8 and 7months of age. However,
seven patients with OSGEP pathogenic variants were alive
at 13 (2), 10.5 (1), 7 (1), 3.5 (1), and 2 (1) years and at 7 (1)
months [2, 10]. It should be noted that four of them car-
ried the above-mentioned OSGEP variant, c.974A >G
p.(Arg325Gln), associated with renal tubular anomalies
[10]. Twenty-two percent (5/23) of patients carrying patho-
genic variants in the WDR73 gene died at a mean age of
8.1 years (ranging from 2.5 to 17 years).
Nearly all OSGEP variants reported as causative of
GAMOS are missense, except for two splicing variants
[2, 8]. These variants are located throughout the OSGEP
gene. By contrast, different types of variant in WDR73
causative of GAMOS have been reported in the litera-
ture, including nonsense (3), frameshift (3), and missense
(4). No correlation seems to exist between the type or
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position of the variant and particular clinical fea-
tures. Identification of the causative pathogenic vari-
ant in patients 1 and 2 confirmed the initial clinical
suspicion of GAMOS and allowed precise genetic
counseling to their parents. In particular, it allowed
prenatal diagnosis of a baby girl without GAMOS
for the parents of patient 1.
In conclusion, we report two patients with GAMOS
caused by OSGEP pathogenic variants. These two
cases, in conjunction with the reported cases in the
literature, add evidence that OSGEP pathogenic vari-
ants are the most prevalent cause of GAMOS and are
associated with a more severe phenotype than WDR73
pathogenic variants. For these reasons, OSGEP variant
analysis should be considered as the first step in gen-
etic diagnosis of patients with clinical suspicion of
GAMOS; this is especially true for those labs that do
not perform massive parallel sequencing and for those
cases with early and severe onset of the disease. Gen-
etic diagnosis of GAMOS is of paramount importance
for genetic counseling and family planning and allows
prenatal or preimplantation genetic diagnosis for fu-
ture pregnancies.
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